Biogen’s Strategic Collaboration Agreement with Skyhawk Therapeutics

On January 4, 2019, Biogen Inc. and Skyhawk Therapeutics, Inc. announced a strategic collaboration in which the companies will leverage Skyhawk’s SkySTAR™ technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the option to license therapies resulting from the collaboration and will be responsible for their development and potential commercialization. The agreement grants Biogen an exclusive license to worldwide intellectual property rights on research‑stage therapeutic candidates for the treatment of multiple sclerosis, spinal muscular atrophy and additional neurological disorders. Cravath is representing Biogen in connection with the transaction.

The Cravath team is led by partners David J. Kappos and G.J. Ligelis Jr. and includes associates Miling Y. Harrington, Bethany A. Pfalzgraf and Michael L. Arnold on M&A and intellectual property matters.